Halozyme Therapeutics | HALO - Capitaux D'Emprunt





Capitaux D'Emprunt Changement Date
Acadia Pharmaceuticals USD 0 0 2025-03
Agios Pharmaceuticals USD 1.06M 0 2022-09
Alnylam Pharmaceuticals USD 2.48B 931K 2026-03
Amgen USD 51.89B 1.88B 2026-03
Baxter International USD 8.62B 852M 2026-03
Cara Therapeutics USD 0 0 2025-03
Cytokinetics USD 247.21M 868.77M 2026-03
DBV Technologies USD 0 0 2025-03
Eli Lilly USD 39.37B 1.5B 2026-03
Esperion Therapeutics USD 457.65M 9.5M 2025-12
Halozyme Therapeutics USD 2.14B 1.34B 2025-12
Intrexon USD 0 198.67M 2024-06
Ionis Pharmaceuticals USD 1.91B 9M 2026-03
MannKind USD 548.44M 244.79M 2025-12
Minerva Neurosciences USD 0 86.58M 2024-09
Nektar Therapeutics USD 63.16M 44.35M 2025-12
Pfizer USD 60.57B 1.08B 2026-03
Rigel Pharmaceuticals USD 0 0 2024-09
United Therapeutics USD 100M 100M 2024-06
Vanda Pharmaceuticals USD 3.15M 3.15M 2024-12